Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study. (CROSBI ID 260738)

Prilog u časopisu | ostalo | međunarodna recenzija

Pulkki, Kari ; Suvisaari, Janne ; Collinson, Paul ; Ravkilde, John ; Stavljenic-Rukavina, Ana ; Hammerer-Lercher, Angelica ; Baum, Hansjorg ; van Dieijen-Visser, Marja ; Laitinen, Paivi A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study. // Clinical chemistry and laboratory medicine, 47 (2009), 227-234. doi: 10.1515/CCLM.2009.044.

Podaci o odgovornosti

Pulkki, Kari ; Suvisaari, Janne ; Collinson, Paul ; Ravkilde, John ; Stavljenic-Rukavina, Ana ; Hammerer-Lercher, Angelica ; Baum, Hansjorg ; van Dieijen-Visser, Marja ; Laitinen, Paivi

engleski

A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study.

A pilot study was performed sponsored by the European Federation of Clinical Chemistry and Laboratory Medicine. A link to an online questionnaire was e-mailed to 990 laboratories from eight European countries in May 2006. The requested information included tests performed, clinical protocol development, and reference limits. We obtained a total of 220 responses. Out of these, 208 responses (95%) were from hospitals that provide 24-h admission of patients. The suggested turn-around-time (<60 min) was apparently met by >88% for cardiac troponin T/I and for CK-MB mass. The majority of the laboratories derive their decision limits from kit inserts provided by the manufacturers. The results revealed a worrying fact that external quality assessments are not used in all testing. Our survey demonstrated that cardiac troponin is the preferred biomarker for the diagnosis of ACS. Half of the participants had written protocols, mostly as a result of collaboration between laboratorians and clinicians.

heart failure ; management recommendation ; guidelines ; carmague

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

47

2009.

227-234

objavljeno

1434-6621

1437-4331

10.1515/CCLM.2009.044.

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost